

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Jorg REIMANN et al.

Art Unit: 1632

Application No.: 09/241,595

Examiner: A. BECKERLEG

Filed: February 2, 1999

Washington, D.C.

For: DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES

Atty.'s Docket: REIMANN=1

Confirmation no. 8928

Date: March 26, 2002

BY HANDCARRY

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:

Transmitted herewith is a [XX] Supplemental Amendment [ ]  
in the above-identified application.

[XX] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted

[ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

[XX] No additional fee is required.

[ ] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 29	MINUS	** 30		0
INDEP.	* 4	MINUS	*** 4		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	

OR

OR

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity  
Response Filed Within

[ ] First - \$ 55.00  
 [ ] Second - \$ 200.00  
 [ ] Third - \$ 460.00  
 [ ] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity  
Response Filed Within

[ ] First - \$ 110.00  
 [ ] Second - \$ 400.00  
 [ ] Third - \$ 920.00  
 [ ] Fourth - \$ 1440.00

Month After Time Period Set

[ ] Less fees (\$ ) already paid for \_\_\_ month(s) extension of time on \_\_\_\_\_.

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_.

[ ] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$\_\_\_\_\_.

[ ] A check in the amount of \$\_\_\_\_\_ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

  
 ALLEN C. YUN  
 Registration No. 37,971

Facsimile: (202) 737-3528  
 Telephone: (202) 628-5197

02 MAR 26 PM 4:02

RECEIVED  
TECH CENTER 1600/2900RECEIVED  
MAR 28 2002  
TECH CENTER 1600/2900

#15  
Supp 1,  
B

RECEIVED 3-29-02  
MAR 26 1990/2300 P. 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 02 MAR 26 PM 4:02

ATTY.'S DOCKET: REIMANN=1

In re Application of:	)	Examiner: A. Beckerleg
Jorg REIMANN et al	)	Art Unit: 1632
Appln. No.: 09/241,595	)	Washington, D.C.
Confirmation No.: 8928	)	
Filed: February 2, 1999	)	March 26, 2002
For: DELIVERY OF IMMUNOGENIC	)	
MOLECULES VIA HBsAg	)	BY HANDCARRY
PARTICLES	)	

TECH CENTER 1600/2900

MAR 28 2002

RECEIVED

SUPPLEMENTAL AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

Supplemental to the Amendment filed February 13, 2002, on which applicants continue to primarily rely, please amend as follows:

IN THE CLAIMS

Please replace claims 1 and 31 with new amended claims 1 and 31 as follows below. A marked up version of the amended claims to show the changes made is attached hereto.

1 (Twice-amended). A method of stimulating or modulating a CTL response to an antigenic molecule in a mammalian subject, comprising administering to said subject an

B'